Neurocrine Biosciences: Tardive Dyskinesia trials

The registry lists 13 Tardive Dyskinesia studies with Neurocrine Biosciences as lead sponsor. 2 are open to participants now and 9 have results posted.

Phase 2 5Phase 3 3Phase 4 4No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive DyskinesiaRecruitingNCT07365462Phase 2
• A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) InhibitorRecruitingNCT07105111Phase 4
• Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive DyskinesiaCompletedNCT05859698Phase 4Results posted
• Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive DyskinesiaCompletedNCT03891862Phase 4Results posted
• The Potential for Clinical Dependence and Withdrawal Symptoms Associated With ValbenazineCompletedNCT03698331Phase 4Results posted
• Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive DyskinesiaCompletedNCT02736955Phase 3Results posted
• Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive DyskinesiaCompletedNCT02405091Phase 3Results posted
• A Phase 3 Study of NBI-98854 for the Treatment of Tardive DyskinesiaCompletedNCT02274558Phase 3Results posted
• NBI-98854 Dose Titration Study for the Treatment of Tardive DyskinesiaCompletedNCT01733121Phase 2Results posted
• NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)CompletedNCT01688037Phase 2Results posted
• NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective DisorderCompletedNCT01393600Phase 2Results posted
• Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic AgentsStatus unknownNCT03062033
• Efficacy and Safety of NBI-98854 in Subjects With Tardive DyskinesiaCompletedNCT01267188Phase 2